pembrolizumab引起甲床溃疡的指甲毒性

IF 1.1 Q4 ALLERGY

Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-09 DOI:10.1002/cia2.12301

Shintaro Maeda MD, PhD, Yasuhito Hamaguchi MD, PhD, Kaori Sawada MD, PhD, Kyoko Shimizu MD, Kyosuke Oishi MD, PhD, Katsushige Taniuchi MD, PhD, Takashi Matsushita MD, PhD

{"title":"pembrolizumab引起甲床溃疡的指甲毒性","authors":"Shintaro Maeda MD, PhD, Yasuhito Hamaguchi MD, PhD, Kaori Sawada MD, PhD, Kyoko Shimizu MD, Kyosuke Oishi MD, PhD, Katsushige Taniuchi MD, PhD, Takashi Matsushita MD, PhD","doi":"10.1002/cia2.12301","DOIUrl":null,"url":null,"abstract":"<p>A 70-year-old Japanese man was diagnosed with bladder cancer and started pembrolizumab. After six courses of pembrolizumab, all fingernails and toenails had fallen off and the nail beds were ulcerated. Pembrolizumab was discontinued, and he was treated with topical steroids and topical prostaglandin E1 ointment.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12301","citationCount":"0","resultStr":"{\"title\":\"Nail toxicity with nail bed ulceration associated with pembrolizumab\",\"authors\":\"Shintaro Maeda MD, PhD, Yasuhito Hamaguchi MD, PhD, Kaori Sawada MD, PhD, Kyoko Shimizu MD, Kyosuke Oishi MD, PhD, Katsushige Taniuchi MD, PhD, Takashi Matsushita MD, PhD\",\"doi\":\"10.1002/cia2.12301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A 70-year-old Japanese man was diagnosed with bladder cancer and started pembrolizumab. After six courses of pembrolizumab, all fingernails and toenails had fallen off and the nail beds were ulcerated. Pembrolizumab was discontinued, and he was treated with topical steroids and topical prostaglandin E1 ointment.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-03-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12301\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12301\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

一名 70 岁的日本男子被诊断出患有膀胱癌，并开始接受 pembrolizumab 治疗。使用 Pembrolizumab 六个疗程后，他的手指甲和脚趾甲全部脱落，甲床溃烂。他停用了 Pembrolizumab，并接受了局部类固醇和局部前列腺素 E1 软膏治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Nail toxicity with nail bed ulceration associated with pembrolizumab

查看原文本刊更多论文

Nail toxicity with nail bed ulceration associated with pembrolizumab

A 70-year-old Japanese man was diagnosed with bladder cancer and started pembrolizumab. After six courses of pembrolizumab, all fingernails and toenails had fallen off and the nail beds were ulcerated. Pembrolizumab was discontinued, and he was treated with topical steroids and topical prostaglandin E1 ointment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cutaneous Immunology and Allergy Medicine-Dermatology

CiteScore

0.60

自引率

10.00%

发文量

审稿时长

12 weeks